CBER FY20 FOA for AAV vector manufacturing for diseases affecting very small populations (R01) Clinical Trial Not Allowed

The Food and Drug Administration (FDA) is seeking to advance the development of gene therapies for diseases affecting very small populations by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors. The FDA is providing funding for research in this area, with a maximum award of $400,000. Eligible applicants include higher education institutions, non-profits, for-profit organizations, and governments. The project aims to improve the manufacture of AAV vectors, which can be used to treat diseases affecting small populations. • The FDA is seeking applications from eligible organizations to conduct research in this area. • The maximum award amount is $400,000. • The project aims to enhance innovations in the manufacture of AAV vectors. • The FDA is seeking to advance the development of gene therapies for diseases affecting very small populations.